Back to Journals » Blood and Lymphatic Cancer: Targets and Therapy » Volume 1

mTOR inhibitor in the treatment of Hodgkin’s lymphoma: a case report

Authors Millán I, Cantos SDI, Provencio M

Published 8 November 2011 Volume 2011:1 Pages 19—22

DOI https://doi.org/10.2147/BLCTT.S24910

Review by Single-blind

Peer reviewer comments 3

Patricia Ibeas, Blanca Cantos, Mariano Provencio
Clinical Oncology Department, Hospital Puerta de Hierro Majadahonda, Madrid, Spain

Abstract: Hodgkin’s disease is curable in 90% of the cases diagnosed in early stages (I and II) and in 70% of all patients who suffer from the disease. Refractory disease occurs in 10%–15% of cases and is still a clinical challenge. Its treatment is based on intensive chemotherapy regimens with transplantation, but there are patients who relapse after transplantation who have a poor prognosis. At this point in time, there is a lack of effective treatment options with proven efficacy and there is a real need to investigate new treatment drugs with different mechanisms of action. A persistent activation of mTOR signaling has been identified in leukemia, Hodgkin’s and non-Hodgkin’s lymphoma, and multiple myeloma. Everolimus, an mTOR kinase inhibitor, is being used as an option in these cases with encouraging results. Here, the authors report their experience with a patient treated with everolimus.

Keywords: everolimus, positron emission tomography, chemotherapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]